Unknown

Dataset Information

0

Probing the Highly Disparate Dual Inhibitory Mechanisms of Novel Quinazoline Derivatives against Mycobacterium tuberculosis Protein Kinases A and B.


ABSTRACT: Mycobacterium tuberculosis (Mtb) serine/threonine (Ser/Thr) Protein kinases A (PknA) and B (PknB) have been identified as highly attractive targets for overcoming drug resistant tuberculosis. A recent lead series optimization study yielded compound 33 which exhibited potencies ~1000 times higher than compound 57. This huge discrepancy left us curious to investigate the mechanistic 'dual' (in)activities of the compound using computational methods, as carried out in this study. Findings revealed that 33 stabilized the PknA and B conformations and reduced their structural activities relative to 57. Optimal stability of 33 in the hydrophobic pockets further induced systemic alterations at the P-loops, catalytic loops, helix Cs and DFG motifs of PknA and B. Comparatively, 57 was more surface-bound with highly unstable motions. Furthermore, 33 demonstrated similar binding patterns in PknA and B, involving conserved residues of their binding pockets. Both ? and hydrogen interactions played crucial roles in the binding of 33, which altogether culminated in high ?Gs for both proteins. On the contrary, the binding of 57 was characterized by unfavorable interactions with possible repulsive effects on its optimal dual binding to both proteins, as evidenced by the relatively lowered ?Gs. These findings would significantly contribute to the rational structure-based design of novel and highly selective dual inhibitors of Mtb PknA and B.

SUBMITTER: Olotu FA 

PROVIDER: S-EPMC7571077 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Probing the Highly Disparate Dual Inhibitory Mechanisms of Novel Quinazoline Derivatives against <i>Mycobacterium tuberculosis</i> Protein Kinases A and B.

Olotu Fisayo A FA   Soliman Mahmoud E ME  

Molecules (Basel, Switzerland) 20200916 18


<i>Mycobacterium tuberculosis</i> (<i>Mtb</i>) serine/threonine (Ser/Thr) Protein kinases A (PknA) and B (PknB) have been identified as highly attractive targets for overcoming drug resistant tuberculosis. A recent lead series optimization study yielded compound <b>33</b> which exhibited potencies ~1000 times higher than compound <b>57</b>. This huge discrepancy left us curious to investigate the mechanistic 'dual' (in)activities of the compound using computational methods, as carried out in thi  ...[more]

Similar Datasets

| S-EPMC6640545 | biostudies-literature
| S-EPMC4242435 | biostudies-literature
| S-EPMC7927854 | biostudies-literature
| S-EPMC7144120 | biostudies-literature
| S-EPMC5090662 | biostudies-literature
| S-EPMC6314710 | biostudies-literature
| S-EPMC3504309 | biostudies-literature
2022-11-02 | PXD035807 | Pride
| S-EPMC3783153 | biostudies-literature
| S-EPMC6761528 | biostudies-literature